UHPLC-ESI-QTOF-MS² analysis of Acacia pennata extract and its effects on glycemic indices, lipid profile, pancreatic and hepatorenal alterations in nicotinamide/streptozotocin-induced diabetic rats

Hui Shao¹ | Minmin Xiao¹ | Zheng Zha¹ | Opeyemi Joshua Olatunji²

Abstract
Diabetes mellitus (DM) is a chronic disorder associated with severe metabolic derangement and comorbidities. The constant increase in the global population of diabetic patients coupled with some prevailing side effects associated with synthetic antidiabetic drugs has necessitated the urgent need for the search for alternative antidiabetic regimens. This study investigated the antidiabetic, antioxidant, and pancreatic protective effects of the Acacia pennata extract (APE) against nicotinamide/streptozotocin induced DM in rats. The antidiabetic activity of APE was evaluated and investigated at doses of 100 and 400 mg/kg body weight, while metformin (150 mg/kg bw) was used as a standard drug. APE markedly decreased blood glucose level, homeostatic model assessment for insulin resistance, serum total cholesterol, triglycerides, low-density lipoprotein, blood urea nitrogen, creatinine, alanine transaminase, aspartate transaminase, and alanine phosphatase levels. Additionally, treatment with APE increased the body weight, serum insulin concentration, and high-density lipoprotein. Moreover, activities of pancreatic superoxide dismutase, catalase, and glutathione peroxidase were increased, while the altered pancreatic architecture in the histopathological examination was notably restored in the treated rats. Ultra-high performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) analysis of APE showcases the prevailing presence of polyphenolic compounds. Conclusively, this study showed the beneficial effects of the Acacia pennata in controlling metabolic derangement, pancreatic and hepatorenal dysfunction in diabetic rats.

Keywords
Acacia pennata, diabetes mellitus, glucose intolerance, oxidative stress, polyphenols, streptozotocin
1 | INTRODUCTION

Diabetes mellitus (DM) is one of the most common metabolic diseases that cut across all age groups and ethnicity. DM is clinically defined as hyperglycemia and it is accompanied by severe deteriorating comorbidities including diabetic nephropathy, neuropathy, reproductive dysfunction, foot ulcer, retinopathy, cardiovascular diseases, depression, and Alzheimer’s disease (Makinde et al., 2020; Song et al., 2021). Statistically, 463 million adults were diabetic in 2019 and the global population of diabetes will increase to 700 million by 2045, and 90% of these reported cases is attributed to type 2 diabetes (IDF Report, 2019). In addition, several millions of people living with diabetes are undiagnosed or are not even aware of their diabetic status (International Diabetes Federation, 2019). Aside the public health burden that DM poses, the significant economic burden associated with DM is very huge. Over 760 billion dollars were expended on diabetes, and it is estimated that 845 billion dollars would be utilized globally for diabetes health-related expenditure (Williams et al., 2020). A relatively sizeable population of people living with diabetes are low-income earners or live in developing nations, where the huge financial burden associated with the treatment of DM is almost not affordable. Furthermore, the antidiabetic drugs currently in clinical use are either not affordable or accessible to most diabetic patients, in addition to the various side effects associated with these drugs (Olatunji et al., 2018; Song et al., 2021). These limitations further increase the morbidity and mortality rates associated with DM. As such, the search for affordable, easily accessible, safer, and indigenous antidiabetic regimens is imperative.

In many countries across the world especially in Asia and Africa, the use of medicinal plants or herbs constitutes a vital part in primary health care due to either religious or cultural beliefs. Specifically, numerous studies have highlighted the relevance of medicinal plants in the treatment of DM and DM-associated comorbidities (Andrade et al., 2020; Farzaei et al., 2017). Additionally, the perceived safety and efficacy index of medical plants has increased their relevance across the globe. Acacia pennata (family: Mimosaceae) is a perennial herb vegetable domiciled in several countries including China, Thailand, Myanmar, and Bangladesh (Kim et al., 2015). In Thailand, the plant is widely used in Thai cuisine. A. pennata is rich in terpenoids and flavonoid glycosides. Traditionally, the plant is used alone or in combination with other plants for treating diabetes, cough, fever, headaches, snake bites, scorpion stings, and rheumatism (Andrade et al., 2020). Regarding pharmacological studies, A. pennata has been reported to possess significant antinociceptive, antioxidant, antimicrobial, anti-inflammatory, α-glucosidase and α-amylase inhibition as well as anti-Alzheimer’s properties (Andrade et al., 2020; Dongmo et al., 2005, 2007; Lomarat et al., 2015). However, studies relating to the antidiabetic effects of the plant are still lacking and there are no scientific reports available to validate its traditional use as an antidiabetic regimen. Therefore, this study investigated the antidiabetic, anti-hyperlipidemic, and antioxidant effects of A. pennata extract in diabetic rats.

2 | MATERIALS AND METHODS

2.1 | Plant material

The aerial part of A. pennata was purchased from a local vegetable market in Hat Yai (Songkla, Thailand) in June 2020, and the identification was performed at the Faculty of Thai Traditional Medicine, Prince of Songkla University, Thailand. A reference sample (#FBR5VP0000270438) was kept at the herbarium of the faculty.

2.2 | Drugs and chemicals

Metformin hydrochloride, nicotinamide, and streptozotocin were purchased from Alfa Aesar. All other chemicals and reagents used were of analytical grade.

2.3 | Preparation of Acacia pennata extract (APE)

The plant was thoroughly cleaned under running tap water and oven dried for 4 days. The dried aerial part of the plant was pulverized with a mechanical grinder. Five hundred grams of the powdered sample was macerated in 70% ethanol at a solvent/solute ratio of 10:1 (v/w) for 24 h on a shaker. The extracted solution was filtered and concentrated to 30% of the original solution using a rotary evaporator. The resulting solution was dechlorophyllized using the sedimentation procedure (Olatunde, Benjakul et al., 2021; Olatunde, Tan et al., 2021). Briefly, the solution of the extract was kept overnight at 4°C. Thereafter, the sample was centrifuged at 10,000 g for 30 min at 4°C. The supernatant was collected and lyophilized. The light brown extract was termed “APE” and stored until further use.

2.4 | UHPLC-DAD-ESI-QTOF-MS profiling of Acacia pennata extract

UPLC-ESI-Q-TOF-MS analysis of APE was performed by solubilizing 50 mg of APE powder in 1 ml of 50% aqueous methanol. The resulting solution was centrifuged and the clear supernatant obtained was subjected to UHPLC-ESI-QTOF-MS analysis using the previously reported protocol (Olatunji et al., 2021).

2.5 | Animals, establishment of diabetes, and treatment

Specific pathogen-free male rats (7 weeks old; 185 ± 20 g) were used for the in vivo antidiabetic experiment. The animals were accommodated in stainless cages and fed with standard rat chow and water ad libitum. Additionally, the animals were maintained at a temperature of 22 ± 2°C, relative humidity of 55 ± 5%, and a 12 h light and dark cycle to simulate natural rhythm. The experimental protocol used
in this study conformed to the guidelines of the National Institutes of Health (NIH, revised 1979) and was approved by the Ethics Committee of the East China Normal University Affiliated Wuhu Hospital (approval number, Wuhuey/2021/0926). The animals were acclimatized to the experimental environment for 1 week. Thereafter, type 2 diabetes mellitus was induced in overnight fasted rats by administering an intraperitoneal injection of 150 mg/kg of nicotinamide 30 min before administering streptozotocin (65 mg/kg, i.p.; Abdel Aziz et al., 2020; Ojuade et al., 2021). Seventy-two hours poststreptozotocin administration, the fasting blood glucose (FBG) level of the overnight fasted rats was determined using Accu-Chek guide glucometer to confirm the establishment of DM. Rats with FBG concentration above 250 mg/dl were adjudged diabetic and incorporated into the study. Diabetic rats were then randomly assigned into four groups of six rats each as follows:

Diabetic control rats (DMR): treated with normal saline.
Positive control rats (PCR): treated with 150 mg/kg of metformin.
APE-1: diabetic rats administered 100 mg/kg of APE.
APE-2: diabetic rats administered 400 mg/kg of APE.

Six healthy nondiabetic rats were designated as normal control (HNR) and were administered normal saline. All the groups were administered their respective treatments once a day per os for 4 weeks. A weekly measurement of the body weight and FBG concentration was performed, while the water and food intake was determined on a daily basis.

2.6 | Posttreatment intraperitoneal glucose tolerance test (IPGTT)

After the treatment, the rats were fasted overnight and a solution of 2 g/kg glucose was intraperitoneally injected into each rat from all the experimental groups. The blood glucose concentration was determined from the blood sample taken from the tail vein of each rat at an interval of 30 min for 120 min (Makinde et al., 2020).

2.7 | Animal sacrifice and biochemical analysis

The rats were anesthetized under thiopental sodium and blood was collected via cardiac puncture, centrifuged to obtain the serum that was used for the determination of lipid profiles, hepatorenal biomarkers, and insulin levels. The pancreas was excised after animal sacrifice for histopathology using routine hematoxylin and eosin (H&E) procedures.

2.8 | Determination of serum biochemical parameters

The serum obtained from the blood samples after centrifugation was used for the determination of serum lipids (triglycerides (TG), total cholesterol (TC), LDL-C, and HDL) and hepatorenal biomarkers (ALT, AST, ALP, creatinine, BUN, and uric acid) using an automated chemistry analyzer (Zhang et al., 2020).

2.9 | Determination of hemoglobin A1c and fasting plasma insulin

Hemoglobin A1c (HbA1c) and fasting plasma insulin (FINS) were determined with enzyme-linked immunosorbent assay (ELISA) kits from the Nanjing Jiancheng Bioengineering Institute (China) according to the protocols of the manufacturer, while HOMA-IR was determined using the formula stated below:

\[
HOMA-IR = \frac{FBG \times FINS}{22.5}
\]

2.10 | Pancreas histological assessment

The pancreas was preserved in 10% neutral buffered formalin solution was used for the histological assessment using routine standard hematoxylin and eosin (H&E) procedures, as previously described (Olatunji et al., 2021).

2.11 | Oxidative stress biomarkers

Oxidative stress parameters including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and malonaldehyde (MDA) levels were determined with biochemical kits from Nanjing Jiancheng Bioengineering Institute following the manufacturer’s instructions (Gao et al., 2021; Olatunji et al., 2017).

2.12 | Statistical analysis

GraphPad Prism 5.0. was used for statistical analysis, and data were presented as mean ± SD (n = 6). Statistical significance was assessed using one-way analysis of variance (ANOVA) followed by a Dunnett post hoc test for comparison between experimental groups. The value of \( p < .05 \) was considered significant.

3 | RESULTS

3.1 | Identification of secondary metabolites in Acacia pennata extract

The identification of the bioactive metabolites in APE was carried out using UHPLC-ESI-QTOF-MS/MS (Figure 1). As shown in Table 1, APE has a robust polyphenolic content ranging from simple phenolic compounds like trolox, to flavones such as baicalein and luteolin. Several flavonoid/phenolic glycosides were identified in the UHPLC-ESI-QTOF-MS/MS analysis of APE, including cynaroside A, rutin, APE-1: diabetic rats administered 100 mg/kg of APE.
APE-2: diabetic rats administered 400 mg/kg of APE.
glucocaffeic acid, patuletin 3-rhamnoside-7-(3',4'-diacetylrhamnoside), Saponarin, luteolin 3'-methyl ether 7,4'-dixyloside, isovitexin, rhamnetin 3-rhamnoside, quercetin 3-rhamnoside-3'-sulfate, and apigenin 7-methyl ether 4'-glucoside. Aside the aforementioned phenolic/polyphenols mentioned above, other secondary metabolites identified in APE include nucleosides; namely 8-hydroxyadenine, adenosine, and isoguanosine. Pyrrolizidine alkaloids including usaramine and rosmarinine were also identified. 8-Deoxy-11,13-dihydroxygrosheimin (sesquiterpene lactone) and oleandolide (macrolide) were also tentatively identified in APE.

### 3.2 | Effect of APE on blood glucose concentration in DM rats

The average FBG concentration in the HNR (95.0 mg/dl) was significantly lower than the DMR rats (420.3 mg/dl) at day 0 of the treatment. At the end of the treatment period (day 28), the FBG level of the HNR was 99.3 mg/dl, which was significantly lower than the corresponding FBG level of the DMR at the same period (509.5 mg/dl). During the course of the treatment, the blood glucose level of the DMR group was consistently and significantly higher than the normal rats (Figure 1a). Whereas in diabetic rats treated with APE (100 and 400 mg/kg), there was a dose-dependent and significant reduction of the FBG concentration to 266.1 and 198.5 mg/dl, respectively, compared to the DMR group at the end of the treatment (Figure 2a).

### 3.3 | Effect of APE on body weight loss, food and water intake in DM rats

Diabetes mellitus significantly increased the food and water consumption of the DMR group when compared to the HNR group (Figure 2b-c). Conversely, treatment of diabetic rats with APE (100 and 400 mg/kg) resulted in significant reduction in the food and water intake of the treated groups compared to the DMR (Figure 1b). Despite the significant increase in the food intake of the DMR group, there was a 17% reduction in the body weight at the end of the study, which was markedly lower than that of the HNR group. The HNR has a 62.6% increase in their body weight (Figure 1c). However, treatment with APE (100 and 400 mg/kg) significantly increased the body weight gain of the treated rats by 29.3 and 33.7%, respectively (Figure 2d).

### 3.4 | Effect on glucose and insulin sensitivity in DM rats

In the IPGTT, the blood glucose concentration of the DMR group was consistently and markedly higher at all the measured times (0, 30, 60, 90, and 120 min), compared to the corresponding values of the rats in the HNR group. Whereas, the glucose sensitivity was significantly reduced in the diabetic rats treated with APE from 60 to 120-min postglucose administration compared to the DMR group (Figure 3a). Additionally, the DMR rats showed significantly reduced FINS levels compared to the HNR group, but significantly improved in APE-treated groups (Figure 3b). Furthermore, HOMA-IR and HbA1c were observed to be significantly increased in the diabetic control group, while treatment of diabetic rats with APE markedly decreased HOMA-IR and HbA1c compared to the DMR group (Figure 3c-d).

### 3.5 | Effect on the serum biochemical parameters in DM rats

The results presented in Figure 4 indicate that the serum lipids including total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) levels in the DMR group were drastically increased (161, 206, and 68.1 mg/dl, respectively), while HDL was reduced compared to the corresponding values in the HNR group (71.3, 69, and 18.8 mg/dl, respectively). Additionally, the serum hepatorenal biomarkers, including ALT, AST, ALP, BUN, creatinine, and uric acid, were significantly increased relative to the HNR group (Figure 5a-f). Conversely, treatment of diabetic rats with APE significantly ameliorated these serum biochemical alterations when compared to the DMR group (Figures 4 and 5).
| No | Rt (min) | Accurate mass (m/z) | Calculated mass | Base peak (m/z) | Score (DB) | Predicted formula | Compound identity |
|----|----------|---------------------|----------------|----------------|------------|------------------|------------------|
| 1  | 2.251    | 191.0562            | 192.0635       | 191.0563       | 99.64      | C₂₅H₁₄O₆        | Quinic acid       |
| 2  | 2.351    | 643.1718            | 644.1797       | 643.1714       | 63.9       | C₁₂H₁₆FeN₂O₅    | Nitrosyl-heme     |
| 3  | 3.807    | 134.0473            | 135.0546       | 134.047        | 87.28      | C₂₁H₂₈N₅        | Adenine           |
| 4  | 4.109    | 150.0418            | 151.0493       | 133.0155       | 78.88      | C₁₂H₉N₂O        | 8-Hydroxyadenine  |
| 5  | 5.138    | 282.0841            | 283.0913       | 283.2639       | 92.9       | C₂₁H₁₈N₂O₅      | Isoguanosine      |
| 6  | 5.188    | 142.0507            | 143.0578       | 142.0504       | 82         | C₂₁H₈NO₃        | Trimethadione      |
| 7  | 5.422    | 243.0508            | 244.0581       | 111.0448       | 99.2       | C₁₀H₁₂O₇        | 1-O-Galloylglycerol|
| 8  | 6.117    | 387.0722            | 388.0785       | 387.0719       | 65.39      | C₂₁H₉O₉         | Urolithin B 3-O-gluconolide |
| 9  | 6.142    | 301.0564            | 302.0638       | 301.056        | 91.75      | C₂₁H₁₈N₂O₅      | Nicarbazin         |
| 10 | 6.318    | 323.1348            | 324.1421       | 323.1347       | 99.88      | C₂₁H₂₀N₂O₅      | p-Hydroxyphenylbutazone |
| 11 | 6.493    | 353.0876            | 354.0949       | 191.0557       | 98.26      | C₁₄H₂₀O₉        | Chlorogenic acid   |
| 12 | 6.519    | 443.192             | 444.1993       | 443.1918       | 98.27      | C₂₃H₂₀O₁₀        | Cynaroside A       |
| 13 | 6.744    | 285.0616            | 286.0688       | 285.0612       | 99.89      | C₂₁H₁₄O₈        | Uralennoseide      |
| 14 | 6.82     | 609.1468            | 610.154        | 609.146        |            |                  |                  |
| 15 | 6.945    | 263.0772            | 264.0846       | 245.0666       | 97.16      | C₂₁H₁₄O₈        | 3-Hydroxy-4-butanolide |
| 16 | 6.958    | 581.1516            | 582.1586       | 581.1508       | 98.53      | C₂₉H₃₀O₁₅       | Norrufrofusarin 6-beta-gentiobioside |
| 17 | 6.97     | 341.0877            | 342.0953       | 341.09         | 90.99      | C₁₅H₁₈O₉        | Glucocaffeic acid  |
| 18 | 7.07     | 707.1829            | 708.1902       | 353.0873       | 99.39      | C₂₁H₂₈O₁₈       | Patuletin 3-rhamnoside–7-(3',4''',5'''-diacetyl) |
3.6 | Effect on pancreas histology in DM rats

The representative H&E-stained pancreas of the HNR group indicated significant number and size of the islet of Langerhans, compared to the DMR group with a reduced islet size as well as necrotic acinar cells (Figure 6a,b). The representative images from the pancreas of APE (100 and 400 mg/kg) and metformin-treated groups showed restored islet of Langerhans cellularity, as indicated by increased size of the islets as well as improved pancreas acinar cells (Figure 6).

3.7 | Effect on oxidative stress biomarkers in DM rats

As shown in Table 2, DM markedly increased pancreatic MDA level in the DMR group compared with the HNR. However, the administration of APE and metformin significantly lowered MDA levels in the pancreas compared with the DMR group. The modulatory effects of APE treatment on antioxidant capacity in diabetic rats are also portrayed in Table 2. In line with the MDA results, the activities of antioxidant enzyme biomarkers including SOD, GPx, and CAT were significantly declined in the pancreatic tissues of the DMR group. In contrast, the rats treated with APE and metformin displayed significant increases in GPx, SOD, and CAT activities in the pancreatic tissues of the treated rats compared to the DMR group (Table 2).

4 | DISCUSSION

Impaired insulin resistance/secrection is the major cause of type 2 diabetes mellitus and it is often characterized by impairment in β-cell function, protein, lipids, and carbohydrate metabolism (DeFronzo et al., 2015; Olatunji et al., 2018). The increase in the incidence and prevalence of DM on the global scale as well as the morbidity/mortality rate associated with comorbidities in diabetes coupled with the unpleasant side effects of contemporary synthetic antidiabetic drugs has fueled the drive for the discovery of alternative sources
for preventing or treating diabetes mellitus (Artasensi et al., 2020; Babar et al., 2019; Williams et al., 2020). As such, exploring medicinal plants as therapeutics for diabetes may be a viable option for counteracting the problems relating to adverse effects, cost, and availability. The present study is the first to demonstrate the antidiabetic effects of APE. The results indicated that APE alleviated diabetes-associated pancreato-hepatorenal dysfunction by decreasing oxidative stress, glucose, and insulin sensitivity in NICO/STZ-induced diabetic rats. Diabetic rats presented significantly increased FBG, serum lipids (TC, TG, and LDL-C), liver and kidney function (ALT, ALP, AST, BUN, and creatinine), reduced serum FINS, and antioxidant enzymes (GPx, SOD, and CAT) as well as significant increases in the lipid peroxidation (MDA) in the pancreas of NICO/STZ-induced DM rats. These results agreed with previous reports that indicated diabetic rats presented impaired kidney, liver, and pancreatic function as well as increased oxidative stress in vital organs (Gao et al., 2021; Makinde et al., 2020; Olatunji et al., 2017). The results of the present study showed that treatment with APE significantly
increased insulin secretion, reduced glucose sensitivity deficits, lipid profiles, oxidative stress, ameliorated β-cell function, and improved islet structure in NICO/STZ-induced DM rats.

Under normal physiological state, the body converts excessive glucose in the blood to glycogen through the stimulation of insulin. Whereas, in type 2 diabetes, insulin secretion/sensitivity is impaired.
resulting in reduced production of insulin which invariably leads to decrease in hepatic glucose conversion to glycogen, cumulating in a high level of glucose in the blood. Additionally, insulin is also responsible for the activation of lipoprotein lipase, a vital enzyme responsible for removing circulating triglycerides in the blood. As such, the insufficiency in insulin concentration experienced in DM results in low circulating lipoprotein lipase enzymes and high lipid accumulation in the blood. These conditions have been linked to a high incidence of cardiovascular diseases in diabetic patients (Mollica et al., 2017; Tan et al., 2006). Thus, regulating insulin secretion can improve glucose conversion, synthesis of lipids, and blood glucose level. The result obtained from this study indicated that APE markedly increased insulin secretion, islets cellularity, and ameliorated pancreatic architecture in diabetic rats, which in turn led to decrease in the blood glucose and lipid profile concentrations. Treatment with APE resulted in significant reduction in blood glucose, TG, TC, and LDL-C levels.

The oral administration of APE significantly altered diabetes-induced hepatorenal dysfunction, as indicated by a reduction in functional biomarkers of the liver (ALT, AST, and ALP) and kidney (BUN, uric acid, and Scr). Diabetes has been strongly implicated in liver and kidney abnormalities. The release of markers of hepatotoxicity including ALP, AST, and ALT into the blood suggests hepatic injury (Adefegha et al., 2014). The liver is critically involved in several physiological processes including insulin clearance, glucose regulation, lipid and carbohydrate metabolism, and deficiencies in insulin function can cause liver abnormalities due to gluconeogenesis, resulting in increased serum liver enzymes (Ghosh & Suryawanshi, 2001). Furthermore, diabetic rats showed increased levels of typical biomarkers of renal injury including high levels of serum BUN, urea, and creatinine which are consistent with previous studies (Kishore et al., 2017; Kpemissi et al., 2020; Zhang et al., 2020). Treatment of diabetic rats with APE resulted in a dose-dependent amelioration of serum hepatorenal dysregulated biomarkers. APE significantly decreased BUN, creatinine, uric acid, AST, ALT, and ALP levels.

Hyperglycemia plays a vital role in the generation of reactive oxygen and oxidative stress. Indeed, accumulating lines of evidence have showcased the prominent role of oxidative stress in the development and progression of comorbidities in diabetes (Marvibaigi et al., 2021). Increased oxidative stress has also been implicated in insulin resistance and β-cell injury resulting in a decline in insulin secretion (Gao et al., 2021). In agreement with previous reports, this study demonstrated oxidative imbalance in the redox status of the pancreas of DM rats, as observed by decreased pancreatic antioxidant activities including GPx, SOD, and CAT, as well as increased levels of MDA. These antioxidants are present in cells, organs, and tissues and they assist in preventing oxidative damage caused by free radicals (An et al., 2020; Samadi-Noshahr et al., 2020; Song et al., 2021). The oral administration of APE significantly improved the activities of GPx, CAT, and SOD in the pancreas of diabetic-treated rats. In addition, the elevated level of MDA was markedly improved upon APE treatment, suggesting the antioxidant effect of APE in diabetic tissue injury.

According to previous studies, the extracts obtained from A. pennata showed robust antioxidant activity and markedly protected against acetaminophen-induced reactive oxygen species (ROS) generation in liver tissues of treated rats (El-Taheer et al., 2021). Consistently, the results from our experiments showed that APE demonstrated anti-diabetic and antioxidant properties, suggesting its favorable alleviative effects on ROS and oxidative damage in DM. The result on the tentative identification of bioactive compounds using UPLC-ESI-MS/MS analysis showed the presence of different polyphenolic compounds in APE, majorly flavonoid glycosides including cynaroside A, rutin, glucocaffeic acid, patuletin 3-rhamnoside-7-(3″,4″-diacetyl)-O-rhamnoside), Saponarin, luteolin 3′-methyl ether 7′,4′-dixyloside, isovitexin, rhamnetin 3-rhamnoside, nelumboside, querctin 3-rhamnoside-3′-sulfate, and apigenin 7-methyl ether 4′-glucoside. Several nonglycosylated phenolic derivatives, such as chlorogenic acid, 3-O-caffeoyl-4-O-methylquinic acid, trolox, luteolin, and

| Groups | MDA (nmol/mg prot) | GPx (U/mg prot) | SOD (U/mg prot) | CAT (U/mg prot) |
|--------|-------------------|----------------|----------------|----------------|
| HNR    | 10.47 ± 1.45      | 250.91 ± 21.28 | 129.91 ± 10.34 | 78.61 ± 9.77   |
| DMR    | 35.01 ± 5.10*     | 119.75 ± 17.66*| 61.61 ± 8.74*  | 31.14 ± 6.50*  |
| APE-1  | 22.86 ± 3.48**    | 170.51 ± 17.33**| 88.8 ± 8.12**  | 55.61 ± 5.02** |
| APE-2  | 16.13 ± 3.48**    | 192.83 ± 9.77**| 106.86 ± 6.31**| 65.38 ± 5.05** |
| PCR    | 17.61 ± 3.03**    | 184.4 ± 14.54**| 107.78 ± 8.60**| 68.3 ± 6.24**  |

**p < .001 compared with the HNR group.
*p < .001 compared with the DMR group.

TABLE 2 Effect of the Acacia pennata extract (APE) on pancreatic oxidative stress and antioxidant parameters nicotinamide/streptozotocin (NICO/STZ)-induced diabetic rats
baicalein, were also identified. The identification of these classes of compounds in APE is consistent with those of previous studies. For instance, EL-Taher et al. identified the presence of nine flavonoid glycosides (including kaempferol 3,7-di-O-hexoside, apigenin 6,8-di-C-hexoside, luteolin-6-C-pentoside-8-C-hexoside, and apigenin-6-C-hexoside-8-C-pentoside) from the leaves of A. pennata using LC–ESI–MS analysis (EL-Taher et al., 2021). In another study, 11 flavonoid glycosides were reported to have been isolated from the aerial parts of A. pennata (Kim et al., 2015). Among the compounds tentatively identified in our study, cynaroside A, rutin, isovitexin, luteolin, and baicalein have been reported as good antidiabetic and antioxidant agents (Fang et al., 2020; Ghorbani, 2017; Wang et al., 2021; Wei et al., 2017). Numerous studies have indicated that diabetes-induced oxidative damages can effectively be mitigated by polyphenolic constituents due to their ability to interfere in the pathophysiology of the disease (Cao et al., 2019; Domínguez Avila et al., 2017; Solayman et al., 2016; Sun et al., 2020). As such, the synergistic hypoglycemic and antioxidant properties of these metabolites may possibly account for the ameliorative effects of APE on the diabetic rats.

5 | CONCLUSION

Taken together, the results presented in this study portrayed the therapeutic effect of APE against NICO/STZ-induced DM. This is evidenced by the ability of APE to alleviate glucose and insulin homeostasis, ameliorate metabolic derangement including dyslipidemia, hepatorenal dysfunction, and restore pancreatic oxidative stress and β-cell function in the treated diabetic animals. These findings may enhance a better understanding of the therapeutic effect of A. pennata on diabetes and the possible development of the plant as for future antidiabetic application. However, further molecular studies are needed to further shed deeper insight into the antidiabetic mechanism of APE.

ACKNOWLEDGMENT

The authors are grateful to East China Normal University Affiliated Wuhu Hospital.

CONFLICT OF INTEREST

None declared by the authors.

DATA AVAILABILITY STATEMENT

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

ORCID

Opeyemi Joshua Olatunji https://orcid.org/0000-0002-6800-4919

REFERENCES

Abdel Aziz, S. M., Ahmed, O. M., Abd El-Twab, S. M., Al-Muzafar, H. M., Amin, K. A., & Abdel-Gabbar, M. (2020). Antihyperglycemic effects and mode of actions of Musa paradisiaca leaf and fruit peel hydroethanolic extracts in nicotinamide/streptozotocin-induced diabetic rats. Evidence-Based Complementary and Alternative Medicine:Ecam, 2020, 9276343.

Adefegha, S. A., Oboh, G., Adefegha, O. M., Boligon, A. A., & Athayde, M. L. (2014). Antihyperglycermic, hypolipidemic, hepatoprotective and antioxidative effects of dietary clove (Syzygium aromaticum) bud powder in a high-fat diet/streptozotocin-induced diabetes rat model. Journal of the Science of Food and Agriculture, 94, 2726–2737.

An, C., Wang, L., Liu, Y., Makinde, E. A., Li, H., & Olatunji, O. J. (2020). Therapeutic effects of 5,7- dihydroxy-6- oxoheptadecanoic acid on dysglycemia, dyslipidemia, and other complications in diabetic rats. Natural Product Communications, 15, 1–7. https://doi.org/10.1177/1934578X20937203

Andrade, C., Gomes, N. G. M., Duangsrisai, S., Andrade, P. B., Pereira, D. M., & Valentão, P. (2020). Medicinal plants utilized in Thai Traditional Medicine for diabetes treatment: Ethnobotanical surveys, scientific evidence and phytochemicals. Journal of Ethnopharmacology, 263, 113177. https://doi.org/10.1016/j.jep.2020.113177

Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020). Type 2 diabetes mellitus: A review of multi-target drugs. Molecules, 25, 1887. https://doi.org/10.3390/molecules25081897

BABAR, Z. U. D., Ramzan, S., El-Dahiyat, F., Tachmazidis, I., Adebisi, A., & Hasan, S. S. (2019). The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries. Frontiers in Pharmacology, 10, 1375. https://doi.org/10.3389/fphar.2019.01375

CAO, H., Ou, J., Chen, L., Zhang, Y., Szkudelski, T., Delmas, D., Daglia, M., & Xiao, J. (2019). Dietary polyphenols and type 2 diabetes: Human study and clinical trial. Critical Reviews in Food Science and Nutrition, 59, 3371–3379. https://doi.org/10.1080/10408398.2018.1492900

DeFronzo, R. A., Ferrannini, E., Groop, L., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., & Weiss, R. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1, 15019. https://doi.org/10.1038/nrdp.2015.19

Domínguez Avila, J. A., Rodrigo García, J., González Aguilar, G. A., & de la Rosa, L. A. (2017). The antidiabetic mechanisms of polyphenols related to increased glucagon-like peptide-1 (GLP1) and insulin signaling. Molecules, 22, 903. https://doi.org/10.3390/molecules22060903

Dongmo, A. B., Nguelefack, T., & Lacaille-Dubois, M. A. (2007). Flavonoids from Acacia pennata and their cytoxycyxygenase (COX-1 and COX-2) inhibitory activities. Planta Medica, 73, 1202–1207.

Dongmo, A. B., Nguelefack, T., & Lacaille-Dubois, M. A. (2005). Antinociceptive and anti-inflammatory activities of Acacia pennata wild (Mimosaceae). Journal of Ethnopharmacology, 98, 201–206. https://doi.org/10.1016/j.jep.2005.01.030

EL-Taher, E. M. M., El-Sherei, M. M., El Dine, R. S., ElNaggar, D. M. Y., Khalil, W. K. B., Kassem, M. S., Elkhateeb, A., & Kassem, M. E. S. (2021). Acacia pennata L. leaves: Chemical profiling and impact on DNA damage, alteration of genotoxicity–related genes expression and ROS generation in hepatic tissues of acetaminophen treated male rats. Advances in Traditional Medicine, https://doi.org/10.1007/s13596-020-00527-6

Fang, P., Yu, M., Shi, M., Bo, P., Gu, X., & Zhang, Z. (2020). Baicalin and its aglycone: A novel approach for treatment of metabolic disorders. Pharmacological Reports, 72, 13–23. https://doi.org/10.1016/j.pharep.2019.00024-x

Farzaei, M., Morovati, M. R., Farjadmand, F., & Farzaei, M. H. (2017). A mechanistic review on medicinal plants used for diabetes
mellitus in traditional Persian medicine. *Journal of Evidence-Based Complementary & Alternative Medicine*, 22, 944–955. https://doi.org/10.1177/1205451419898646

Gao, L., Zhang, W., Yang, L., Fan, H., & Olatunji, O. J. (2021). Stink bean (*Parkia speciosa*) empty pod: A potent natural anti-diabetic agent for the prevention of pancreatic and hepatorenal dysfunction in high fat diet/streptozotocin-induced type 2 diabetes in rats. *Archives of Physiology and Biochemistry*, https://doi.org/10.1080/1381455.2021.1876733

Ghorbani, A. (2017). Mechanisms of anti-diabetic effects of flavonoid rutin. *Biomedicine & Pharmacotherapy*, 96, 305–312. https://doi.org/10.1016/j.biopha.2017.10.001

Ghosh, S., & Suryawanshi, S. A. (2001). Effect of *Vinca rosea* extracts in treatment of alloxan diabetes in male albino rats. *Indian Journal of Experimental Biology*, 39, 748–759.

International Diabetes Federation (2019). *IDF Diabetes Atlas* (p. 9), 9th ed. IDF.

Kim, A., Choi, J., Htwe, K. M., Chin, Y. W., Kim, J., & Yoon, K. D. (2015). Flavonoid glycosides from the aerial parts of *Acacia pennata* in Myanmar. *Phytochemistry*, 118, 17–22. https://doi.org/10.1016/j.phytochem.2015.08.001

Kishore, L., Kaur, N., & Singh, R. (2017). Nephroprotective effect of *Paeonia emodi* via inhibition of advanced glycation end products and oxidative stress in streptozotocin/nicotinamide induced diabetic nephropathy. *Journal of Food and Drug Analysis*, 25, 576–588. https://doi.org/10.1016/j.jfda.2016.08.009

Kpemissi, M., Potárnicz, A. V., Lawson-Evi, P., Metowogo, K., Meila, M., Dramane, P., Taulescu, M., Chandramohan, V., Suhas, D. S., Puneeth, T. A., Kumar, S. V., Vlase, L., Andrei, S., Eku-Gadegbeku, K., Sevastre, B., & Veerapur, V. P. (2020). Nephroprotective effect of *Combretum micranthum* G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In vivo and in-silico experiments. *Journal of Ethnopharmacology*, 261, 113133. https://doi.org/10.1016/j.jep.2020.113133

Lomarat, P., Chancharunee, S., Anantachoke, N., Kitphati, W., Sripa, K., & Bunyaphraphatsara, N. (2015). Bioactivity-guided separation of the active compounds in *Acacia pennata* responsible for the pre-biotic activity of the *Lycium chinense* Mill. On oxidative stress, dyslipidemia, and diabetes mellitus in streptozotocin-nicotinamide induced diabetic rats. *Chemistry & Biodiversity*, 14, e1700277.

Olatunji, O. J., Chen, H., & Zhou, Y. (2017). Effect of the polyphenol rich ethyl acetate fraction from the leaves of *Lycium chinense* Mill. On oxidative stress, dyslipidemia, and diabetes mellitus in streptozotocin-nicotinamide induced diabetic rats. *Chemistry & Biodiversity*, 14, e1700277.

Olatunji, O. J., Chen, H., & Zhou, Y. (2018). *Lycium chinense* leaves extract ameliorates diabetic nephropathy by suppressing hyperglycemia mediated renal oxidative stress and inflammation. *Biomedicine & Pharmacotherapy*, 102, 1145–1151. https://doi.org/10.1016/j.biopha.2018.03.037

Olatunji, O. J., Zuo, J., & Olatunji, O. O. (2021). *Securidaca inapendiculata* stem extract confers robust antioxidant and anti-diabetic effects against high fructose/streptozotocin induced type 2 diabetes in rats. Exploration of bioactive compounds using UHPLC-ESI-QTOF-MS. *Archives of Physiology and Biochemistry*, https://doi.org/10.1080/13813455.2021.1921811

Samadi-Noshravan, Z., Hadjizadeh, M. A., Moradi-Marjaneh, R., & Khajavi-Rad, A. (2020). The hepatoprotective effects of fennel seeds extract and trans-Anethole in streptozotocin-induced liver injury in rats. *Food Sciences and Nutrition*, 9, 1121–1131.

Solayman, M., Ali, Y., Alam, F., Islam, M. A., Alam, N., Khalil, M. I., & Gan, S. H. (2016). Polyphenols: Potential future arsenals in the treatment of diabetes. *Current Pharmaceutical Design*, 22, 1549–1565. https://doi.org/10.2174/13816122166615112500111

Song, P., Sun, C., Li, J., Long, T., Yan, Y., Qin, H., Makinde, E. A., Famurewa, A. C., Jaisi, A., Nie, Y., & Olatunji, O. J. (2021). *Tiliacora triandra* extract and its major constituent attenuates diabetic kidney and testicular impairment by modulating redox imbalance and pro-inflammatory responses in rats. *Journal of the Science of Food and Agriculture*, 101, 1598–1608.

Sun, C., Zhao, C., Guven, E. C., Paoli, P., Simal-Gandara, J., Ramkumar, K. M., Wang, S., Buleu, F., Pah, A., Turi, V., Damian, G., Dragan, S., Tomas, M., Khan, W., Wang, M., Delmas, D., Portillo, M. P., Dar, P., Chen, L., & Xiao, J. (2020). Dietary polyphenols as anti-diabetic agents: Advances and opportunities. *Food Front*, 1, 18–44. https://doi.org/10.1002/ff2.15

Tan, G. D., Oliveira, G., Vidal, H., Frayn, K. N., & Karpe, F. (2006). Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: Role of adipose tissue and skeletal muscle in response to rosiglitazone. *Diabetologia*, 49, 2412–2418. https://doi.org/10.1007/s00125-006-0370-9

Wang, Z., Zeng, M., Wang, Z., Qin, F., Chen, J., & He, Z. (2021). Dietary luteolin: A narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism. *Journal of Agriculture and Food Chemistry*, 69, 1441–1454. https://doi.org/10.1021/acs.jafc.0c08085

Wei, B. B., Chen, Z. X., Liu, M. Y., & Wei, M. J. (2017). Development of a UPLC-MS/MS method for simultaneous determination of six flavonoids in rat plasma after administration of Maydis stigma extract and its application to a comparative pharmacokinetic study in normal and diabetic rats. *Molecules*, 22, 1267. https://doi.org/10.3390/molecules22081267

Williams, R., Kuraranga, S., Malanda, B., Saeedi, P., Basit, A., Besançon, S., Bommer, C., Esteghamati, A., Ogurtsova, K., Zhang, P., & Colagiuri, S. (2020). Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes Research and Clinical Practice*, 162, 108072. https://doi.org/10.1016/j.diabres.2020.108072
Xiang, Z., Xie, H., Tong, Q., Pan, J., Wan, L., Fang, J., & Chen, J. (2021). Revealing hypoglycemic and hypolipidemic mechanism of Xiaokeyinshui extract combination on streptozotocin-induced diabetic mice in high sucrose/high fat diet by metabolomics and lip- idomics. *Biomedicine & Pharmacotherapy, 135*, 111219. https://doi.org/10.1016/j.biopha.2021.111219

Zhang, W., Meng, J., Liu, Q., Makinde, E. A., Lin, Q., & Olatunji, O. J. (2020). *Shorea roxburghii* leaf extract ameliorates hyperglycemia induced abnormalities in high fat/fructose and streptozotocin induced diabetic rats. *Chemistry & Biodiversity, 17*, e1900661.

**How to cite this article:** Shao, H., Xiao, M., Zha, Z., & Olatunj, O. J. (2022). UHPLC-ESI-QTOF-MS² analysis of *Acacia pennata* extract and its effects on glycemic indices, lipid profile, pancreatic and hepatorenal alterations in nicotinamide/ streptozotocin-induced diabetic rats. *Food Science & Nutrition, 10*, 1058–1069. https://doi.org/10.1002/fsn3.2732